Researchers conducting a study to learn if children with a urinary tract disorder known as vesicoureteral reflux should be treated with an antibiotic for an extended period of time are seeking to enroll more participants.

Peptimmune a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis.

MEDIHONEY has been found in a large randomized controlled clinical trial to significantly reduce the presence of methicillin-resistant Staphylococcus aureus in chronic wounds.

In a recently concluded Phase 3 multicenter clinical trial, academic and industry researchers found the use of up to three units of a blood substitute to be relatively safe in patients under 80 with a moderate need for transfusions.

Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia.

Results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP with 90Yttrium Ibritumomab Tiuxetan radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma are promising.

Pharmacyclics announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL).

Rigel reported an abstract providing preliminary results of a Phase 2 clinical trial of its oral Syk inhibitor, R788, in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas.